Publikationen in Zusammenarbeit mit Forschern von University of Alberta (12)

2020

  1. Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2

    Clinical Breast Cancer, Vol. 20, Núm. 2, pp. e173-e180

2019

  1. Assessment of ERBB2 / HER2 Status in HER2 -Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines

    JAMA Oncology, Vol. 5, Núm. 3, pp. 366-375

2017

  1. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

    The Lancet Oncology, Vol. 18, Núm. 12, pp. 1688-1700

2016

  1. HER2 gene amplification testing by fluorescent in situ hybridization (FISH): Comparison of the ASCO-College of American Pathologists guidelines with FISH scores used for enrollment in Breast Cancer International Research Group clinical trials

    Journal of Clinical Oncology, Vol. 34, Núm. 29, pp. 3518-3528

2015

  1. PTEN loss is associated with worse outcome in HER2-Amplified breast cancer patients but is not associated with trastuzumab resistance

    Clinical Cancer Research, Vol. 21, Núm. 9, pp. 2065-2074

  2. Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer

    Journal of Clinical Oncology, Vol. 33, Núm. 2, pp. 141-148

2013

  1. Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, her2-positive early breast cancer: Results from the BCIRG 006 study

    Oncologist, Vol. 18, Núm. 7, pp. 812-818

2012

  1. Analysis of Fcγ receptor IIIa and IIa polymorphisms: Lack of correlation with outcome in trastuzumab-treated breast cancer patients

    Clinical Cancer Research, Vol. 18, Núm. 12, pp. 3478-3486

2009

  1. Reply to L.C. Panasci

    Journal of Clinical Oncology

  2. Reply to R.S. Mehta et al

    Journal of Clinical Oncology

  3. TRIO-012: A multicenter, multinational, randomized, double-blind phase iii study of imc-1121b plus docetaxel versus placebo plus docetaxel in previously untreated patients with her2-negative, unresectable, locally recurrent or metastatic breast cancer

    Clinical Breast Cancer, Vol. 9, Núm. 4, pp. 258-261

2007

  1. Benefit from adjuvant taxanes and endocrine responsiveness in breast cancer

    Breast, Vol. 16, Núm. 2 SUPPL., pp. 127-131